Baird Financial Group Inc. Sells 6,500 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Baird Financial Group reduced its IDEXX Laboratories stake by 7.9% in the second quarter, selling 6,500 shares and retaining 76,035 shares valued at approximately $40 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly adjusted earnings of $4.27 per share, exceeding the $3.94 consensus estimate, while revenue rose 9.7% year over year to $1.22 billion. The company issued fiscal 2026 EPS guidance of $14.69–$14.94.
• Analyst sentiment remains positive but cautious, with six Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $747, well above the stock’s reported $515.15 price.

Baird Financial Group Inc. decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,035 shares of the company's stock after selling 6,500 shares during the period. Baird Financial Group Inc. owned 0.10% of IDEXX Laboratories worth $40,028,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Empowered Funds LLC lifted its holdings in shares of IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC bought a new position in IDEXX Laboratories during the 2nd quarter worth about $265,000. Jump Financial LLC grew its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company's stock worth $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $164,000. Finally, Sei Investments Co. increased its position in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company's stock valued at $64,678,000 after purchasing an additional 82,755 shares during the period. Institutional investors own 87.84% of the company's stock.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.79% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. UBS Group boosted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Finally, Weiss Ratings cut IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Stock Performance

IDXX opened at $515.15 on Thursday. The company has a market cap of $40.58 billion, a P/E ratio of 36.23, a price-to-earnings-growth ratio of 2.78 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The firm's 50-day moving average price is $557.68 and its 200-day moving average price is $567.79. IDEXX Laboratories, Inc. has a 52-week low of $511.16 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.